At Rush University Medical Center, we are putting your safety first. For information about COVID-19, see the latest updates. Rush accepts donations to support our response effort, staff, and patients and families.

Excellence is just the beginning.

Translate

French German Italian Portuguese Russian

Treatment Study for Patients with HER2-Expressing Cancers

Clinical Trial Title: 
Phase I trial of ZW25 in patients with locally advanced (unresectable) and/or metastatic HER2-expressing cancers.
Clinical Trial Protocol ID: 
17051706
Clinical Trial Investigator Name: 
Melody A. Cobleigh, MD
Clinical Trial Protocol Description: 

To evaluate the maximal tolerated dose (MTD), optimal biological dose (OBD) or other recommended dose (RD), and overall safety and tolerability of ZW25 in patients with locally advanced (unresectable) and/or metastatic HER2-expressing cancers.

Clinical Trial Eligibility Criteria: 

In order to participate you must meet the following criteria:

  • Have HER2-expressing cancer.
  • Have an ECOG of 0 or 1.
  • Have adequate renal function.
  • Are at least 18 years of age.

This is a partial list of elgibility requirements.

Clinical Trial Area: 
Blood Disorders and Hematologic Cancers
Gastrointestinal Cancers
Contact Email: 
Contact Phone: 
(312) CANCER-1
Contact Name: 
Rush Cancer Center Clinical Trials Office